Apellis Pharmaceuticals Inc Earnings

Apellis Pharmaceuticals Inc’s revenue fell -5.94% since last year same period to $199.91Mn in the Q4 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -56.41% fall in its revenue since last 3-months.

Apellis Pharmaceuticals Inc’s net profit fell -62.16% since last year same period to $-58.95Mn in the Q4 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -127.33% fall in its net profits since last 3-months.

Apellis Pharmaceuticals Inc’s net profit margin fell -72.4% since last year same period to -29.49% in the Q4 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -162.69% fall in its net profit margins since last 3-months.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.44 - a -17.34% fall from last quarter’s estimates.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.44.

Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Apellis Pharmaceuticals Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.